The fact that antimicrobial resistance (AMR) represents a "ticking time bomb" and a major threat to global health is widely recognized by governments, the scientific community and the biopharmaceutical industry alike. Yet, despite that consensus, advocacy groups focusing on the problem argue that when all is said and done there is more being said than done. As a result, the pace of progress and the amount investments being made in research and development need to be accelerated.